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Abstract Bronchoalveolar lavage (BAL) is a pul-
monary sampling technique for characterization of drug
concentrations in epithelial lining fluid and alveolar
cells. Two hypothetical drugs with different pulmonary
distribution rates (fast and slow) were considered. An
optimized BAL sampling design was generated assuming
no previous information regarding the pulmonary dis-
tribution (rate and extent) and with a maximum of two
samples per subject. Simulations were performed to
evaluate the impact of the number of samples per subject
(1 or 2) and the sample size on the relative bias and
relative root mean square error of the parameter esti-
mates (rate and extent of pulmonary distribution). The
optimized BAL sampling design depends on a charac-
terized plasma concentration time profile, a population
plasma pharmacokinetic model, the limit of quantifica-
tion (LOQ) of the BAL method and involves only two
BAL sample time points, one early and one late. The
early sample should be taken as early as possible, where
concentrations in the BAL fluid C LOQ. The second
sample should be taken at a time point in the declining
part of the plasma curve, where the plasma concentration
is equivalent to the plasma concentration in the early
sample. Using a previously described general pulmonary
distribution model linked to a plasma population phar-
macokinetic model, simulated data using the final BAL
sampling design enabled characterization of both the rate
and extent of pulmonary distribution. The optimized
BAL sampling design enables characterization of both
the rate and extent of the pulmonary distribution for both
fast and slowly equilibrating drugs.
Keywords Bronchoalveolar lavage  Pulmonary
distribution  Sampling design  Pharmacometrics
Introduction
To combat and prevent further rise in antibiotic resistance,
antibiotic dosing regimens needs to be based on pharma-
cokinetics (PK) and pharmacodynamics (PD). Direct
measurements of antibiotic concentrations close or at the
site of infection as opposed to plasma concentrations have
been promoted for antibiotics due to possible differences in
distribution to various tissues. The distribution to the site of
action from plasma will directly have impact on the rela-
tionship between concentrations in plasma and concentra-
tions at the site of action. Basic pharmacodynamic
principles further dictate that the observed drug effect is
directly dependent on the drug concentration. Thus, if the
drug carries out its effect in a tissue other than where drug
concentration is measured, the possibility of a discrepancy
between measured concentration and observed effect
exists. The effect could then potentially be better correlated
to the concentration at the site of action. This possibility is
one of the reasons behind the development of methods
allowing for quantification of drug concentrations close to
or at the site of action, in order to possibly better be able to
describe exposure–response relationships.
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Bronchoalveolar lavage (BAL) is a semi-invasive
method used in both research and clinical practice as a way
of quantifying drug concentrations from epithelial lining
fluid (ELF) and alveolar cells (AC) [1–5]. For pulmonary
infections, concentrations of antibiotics in ELF for extra-
cellular pathogens and alveolar macrophage (AM) cells for
intracellular pathogens have for example been proposed to
reflect antibiotic activity in pneumonia [4]. Capturing the
drug concentration ratio between plasma and ELF or AC is
thus of importance in order to guarantee that sufficient drug
concentrations reach the pulmonary tract. It is however
important not only to characterize the extent of distribution
to ELF or AC but also characterize the rate of distribution
from plasma when obtaining relationships between PK and
PD. This is especially relevant for drugs and compounds
without an instantaneous or fast equilibrium between
plasma and the lung, where the exposure in plasma may not
be a good marker of the drug exposure at the site of action.
This could potentially lead to a distorted PKPD
relationship.
In a review by Rodvold et al [3], the penetration of
various anti-infective agents into ELF was summarized.
One of the conclusions in the review was that many studies
involving BAL sampling are not designed to enable
description of both the extent and rate of distribution of
drug concentrations from plasma to pulmonary tissue. Due
to the semi-invasive nature of the BAL method, only one or
two samples is often taken from each subject. This results
in that it is impossible to describe a full distribution profile
from each subject. One way of dealing with this is by
dividing the study population into subgroups and conduct
sampling of these subgroups at different times after dose
[6–8]. This approach compared to the single sample
approach, that only provides a snapshot of the distribution
at the time of sampling, enables a potential characterization
of both the rate and extent of distribution. Both methods
further try to capture both the peak concentration and the
minimum concentration in ELF or AC. This to maximize
the information gained when using the quantified concen-
trations in plasma, ELF or AC to calculate concentration
ratios or exposure. Both sampling methods however
require previous knowledge regarding the pulmonary dis-
tribution of the drug to capture both the peak and the
minimum drug concentrations. For a novel compound,
where nothing or very little is previously known with
regards to its pulmonary distribution, these sampling
strategies will be difficult to implement due to that the time
of the peak and minimum ELF and AC concentrations are
unknown. Important to realize is also that a study design
capturing only point estimates of concentrations cannot be
used for simulation purposes. In a publication by Clewe
et al [9], a pharmacometric model enabling characteriza-
tion of both the rate and extent of drug distribution from
plasma to ELF and AC was developed using rifampicin
(RIF) as an example. The model was developed on single
time point estimate data and in the publication limitations,
with regards to this kind of data, in describing the rate of
distribution from plasma is discussed. The data used in the
publication by Clewe et al [9], consisting of RIF concen-
trations quantified in ELF and AC at approximately 4 h and
in plasma at 2 and 4 h after dose, contained no information
to enable a correct characterization of the distribution rates
from plasma to ELF and AC. Thus forcing the assumption
of instantaneous distribution. A similar model structure as
the general pulmonary distribution model has been pre-
sented earlier in an example of drug distribution to pul-
monary lesions in rabbit [10]. The general pulmonary
distribution model applied in this work [9] constitutes an
approach for characterizing the ratio (extent) and rate of
distribution to ELF and/or AC which is not dependent on
an individual rich pharmacokinetic BAL sampling or
sampling at many different time points between subjects.
The approach is further to be viewed as drug unspecific as
the general pulmonary distribution model can be linked to
any type of plasma PK model, not only to the plasma PK
model used as an example in the publication by Clewe et al
[9].
Modeling and simulation has previously been success-
fully used to provide information on aspects related to
study design [11, 12] and should in the field of biomedical
science now be considered as an integral part of research
and development [13, 14]. Evaluation in a clinical data
setting cannot be used for validation of the approach.
Validation of the approach is commonly done using sim-
ulation and estimation techniques [11, 12]. In such an
approach the simulations are made for different designs
and the parameter estimates that are re-estimated are
benchmarked against the true parameter estimates. In a
clinical data setting, the true parameter estimates are never
known and bias and precision given a specific design
cannot be evaluated. The aim of this work was thus to
develop and evaluate a general optimized BAL sampling
design, making use of a previously published pharmaco-
metric modeling approach for describing pulmonary dis-
tribution [9], that would allow for characterization of both
the rate and extent of distribution from plasma to ELF or
AC for two hypothetical drugs with different distribution
rates (fast and slow). The optimization of the sampling
design does however not make use of the concept of
optimal design theory for non-linear mixed effects models
[15, 16], which involves some type of optimality criteria
and maximization of the Fisher information matrix (FIM).
Relative bias and relative root mean square error (rRMSE)
in the parameter estimates were evaluated using simula-
tions for different number of samples per subject (1 or 2)
and total sample size.
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Materials and methods
A previously developed pharmacometric modeling
approach enabling characterization of pulmonary distribu-
tion in the form of rate and ratio (extent) of distribution
from plasma to ELF and AC [9] was used as a basis for the
sampling design evaluation. The previously published
modeling approach was developed using RIF plasma and
BAL data and hence consisted of a RIF plasma PK model
















where C is concentration, kELF is the distribution rate
constant for the transfer of drug from plasma to ELF,
RELF/plasma is the ELF/plasma concentration distribution
ratio (extent), kAC is the distribution rate constant for the
transfer of drug from plasma to AC and RAC/plasma is the
AC/plasma concentration distribution ratio (extent).
Aplasma/Vplasma is the concentration of drug predicted in the
plasma compartment at time t, with Aplasma being the
amount of drug in plasma and Vplasma being the apparent
plasma volume of distribution.
The basis for the sampling design was that a maximum
of two samples was to be taken from the same individual
within a time frame of 24 h. Further, the approach assumed
that the studied drug’s plasma concentration profile and the
LOQ for the drug in the BAL sample is known. In the
publication by Clewe et al [9], a RIF plasma PK model was
used an example of a drug plasma PK model. This RIF
plasma PK model (Fig. 2) was in this study used as an
example of a plasma PK model. Characterization of the
typical plasma concentration was done by simulations with
the plasma PK model (Fig. 1). The LOQ was set to the
values reported (plasma 0.5 and 0.015 mg/L for the BAL
sample) for the data [1] used in the publication by Clewe
et al [9]. The plasma to ELF and AC distribution was in the
model by Clewe et al [9] described separately with two
different distribution rate constants and distribution ratios
(extents) for ELF and AC (Eqs. 1, 2). In this study only one









In Eq. 3, C is concentration in the pulmonary com-
partment, k is the distribution rate constant for the distri-
bution of drug from plasma to the pulmonary compartment,
R is the pulmonary to plasma concentration distribution
ratio (extent). Aplasma/Vplasma is the concentration of drug
predicted in the plasma compartment at time t, with Aplasma
being the amount of drug in plasma and Vplasma being the
apparent plasma volume of distribution. This one pul-
monary compartment could thus represent either the dis-
tribution from plasma to ELF, AC or both. A schematic
illustration of the model used for the evaluation of the
sampling design is shown in Fig. 2. To illustrate the
models ability of handling different distribution scenarios,
simulations with different distribution rate constants
(k) and different distribution ratios (extents) (R) were
performed. The results from the simulations shows that the
model well handles different distribution rates (Online
Resource 1) and ratios (extents) (Online Resource 2).
Based on the simulated plasma concentration versus
time profile (Fig. 1), two time points for the BAL sampling
were selected. These two samples needs to be taken at two
time points where the plasma concentration is the same i.e.
one sample in the raising part of the plasma concentration
time profile and one in the declining part of the plasma
concentration time profile. In addition, the time points
needs to be selected in order to maximize the likelihood of
that the BAL concentrations are above the BAL LOQ.
Most often, the rate of pulmonary distribution is not
Fig. 1 Simulated typical plasma concentrations versus time after a
single 600 mg oral dose (black solid line) based on final estimates
from the population pharmacokinetic model [9]. The grey dashed line
represents the limit of quantification (LOQ), 0.05 mg/L, of rifampicin
in bronchoalveolar lavage (BAL) fluid (epithelial fluid or alveolar
cells). The identified optimized rifampicin BAL sampling time points
are marked on the x-axis and were 1 and 13 h post dose. The sampling
time points should be as early and as late as possible within the study
time frame and were selected from the simulated plasma concentra-
tion time profile based on correspondence in plasma concentrations;
plasma concentrations C LOQ in BAL fluid and maximizing BAL
fluid concentrations C LOQ in BAL fluid assuming a slow
distribution
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known. If the distribution is perfusion limited, the BAL
concentration profile will follow the plasma profile in the
raising part of the concentration profile. In the case of a
distribution rate limitation, the BAL concentration profile
may increase slower than the plasma profile and as such, it
may take longer time until the BAL concentrations are
above the BAL LOQ. Taking this into account, simulations
with the general pulmonary distribution model (Fig. 2) and
a slow distribution rate, equal to a distribution half-life of
2 h, was performed. The sampling time points chosen,
based on the plasma concentration time profile and the
BAL LOQ, was reevaluated based on correspondence
between the plasma concentrations in the early and the late
sample and the extent of pulmonary concentrations\BAL
LOQ at the time of sampling. Based on this a first sampling
time at 1 h after dose was chosen. The late sample should
be taken in the descending part of the time concentration
profile, at a time point when the plasma concentration is
corresponding (i.e. equal) to the plasma concentration at
the first sampling time point and being[ the BAL LOQ. In
this case, 13 h was the corresponding time point to the 1 h
early sample.
The characterization of pulmonary distribution of RIF
and antibiotics aimed at the pulmonary tract in general has
been heavily focused on the ratio between ELF, AC and
plasma [1–4]. It is as however also interesting to describe
the rate of distribution. We therefore assumed a fast and a
slow distribution rate as two possible characteristics. In the
fast scenario, the rate of distribution between plasma and
the pulmonary tract, k, was 41.6 h-1 equivalent to an
almost instantaneous distribution (1 min) of drug from
plasma to the pulmonary tract. In the second scenario, a
slow (2 h) distribution rate (k = 0.35 h-1) between plasma
and the pulmonary tract was assumed. Inter individual
variability (IIV) in the distribution extent parameter
(R) was only estimated in the simulations of designs with 2
samples per subject, and then fixed to 30 %.
A number of different study scenarios (Online Resource
3) for the fast and slow pulmonary distribution character-
istics were considered. The study scenarios were varied
with regards to samples taken per subject (1 or 2) and
sample size (10, 20, 30 or 50 subjects). For the 1 sample
per subject design half of the total subjects were sampled at
the early time point and the other half at the late time point.
As the PK model by Clewe et al [9] included allometric
scaling of clearance and plasma volume by fat free mass
(FFM), each subject added to the datasets was given a
weight and height based on mean and standard deviations
from a standard, male, reference population [18]. Individ-
ual FFM values (FFMi), assuming a male study population,
were calculated as:
FFMi ¼ WHSMAX  HT
2 WT
WHS50  HT2 þWT ð4Þ
where the maximal weight height squared (WHSMAX) is
42.92 kg/m2 and WHS50 is 30.93 kg/m
2.
The Stochastic Simulation and Estimation tool (SSE) as
provided in the Perl speaks NONMEM (PsN) software,
version 4.4.3 [19] together with the software NONMEM,
version 7.3 (Icon Development Solutions, Ellicot City,
USA) [20], was used to create 1000 datasets for each
scenario, simulating individual plasma and pulmonary
concentrations using the model (Fig. 2) using the first order
conditional estimation method with interaction (FOCE
INTER). Estimation of k, R, residual error, and where
applicable the IIV in R, was the carried out using the
simulated data. The plasma PK parameters including IIV
estimates from the publication by Clewe et al [9] were
fixed but the simulated plasma concentrations were
retained in the model i.e. a PPP&D approach [21]. Relative
bias (%) and rRMSE (%) in the parameter estimates were
calculated according to Eqs. 5 and 6, respectively.















where esti represents the estimated typical population
parameter value and truei represents the true typical pop-
ulation estimate for the parameter.
Fig. 2 Schematic representation of the pharmacokinetic model [17]
and the general pulmonary distribution model [9] used for the
simulations and the evaluation of the bronchoalveolar lavage (BAL)
sample design. Drug is transferred via a number of transit absorption
compartments to the absorption compartment and further via the rate
constant ka to the central plasma compartment. Auto-induction is
described with an enzyme turn-over model in which the drug plasma
concentration increased the enzyme production rate (kENZ) which in
turn increased the enzyme pool (Enz) in a non-linear fashion by
means of an EMAX-model. Cp is the drug plasma concentration and
Emax is the maximal auto-induction of oral clearance (CL/F). EC50 is
the drug concentration resulting in 50 % of the maximal auto-
induction of CL/F. The general pulmonary distribution model
includes the distribution rate constant (k) for the transfer of drug
from plasma to BAL fluid (epithelial lining fluid or alveolar cells).
R is the BAL fluid/plasma concentration distribution ratio (extent)
702 J Pharmacokinet Pharmacodyn (2015) 42:699–708
123
Results
The results from the evaluation, utilizing sampling time
points at 1 and 13 h after dose, of the different scenarios
are shown in Figs. 3, 4, 5, 6, 7, and 8 and in Online
Resource 4. For the fast pulmonary distribution scenarios
(1–12) using a 1 sample per subject design, both rRMSE
and relative bias decreased for the parameter estimates of
R and the residual error with increasing sample size. The
rRMSE in R decreased from 16.2 % (10 subjects) to 7.7 %
(50 subjects) and from 66 % (10 subjects) to 29.5 % (50
subjects) for the residual error. The relative bias in R in-
creased slightly from -1.6 % (10 subjects) to -2.6 % (50
subjects) when increasing the number of subjects. The
relative bias in the residual error decreased from -16.4 %
(10 subjects) to -12.1 % (50 subjects). The evaluation
using the same distribution rate (fast) but with 2 samples
per subject shows similar trends but with an overall lower
relative bias and rRMSE in the parameter estimates for the
different study population sizes compared to the 1 sample
per subject scenarios. For the 2 samples per subject sce-
narios (5–8), rRMSE decreases from 12.3 % (10 subjects)
to 5.6 % (50 subjects) and from 46.2 % (10 subjects) to
23.3 % (50 subjects) in the estimation of R and the residual
error, respectively. Relative bias in the R parameter
increased slightly when increasing the sample size from 10
to 50 subjects, ?0.02. The relative bias in the residual error
decreased from from -14.2 % (10 subjects) to -11.8 %
(50 subjects). Taking 2 samples per subjects with the fast
distribution from plasma to ELF also allowed for including
IIV on the R parameter (scenario 9–12). The rRMSE for the
parameter estimates of R, IIV in R and the residual error
decreased with increasing sample size; from 17.2 % (10
subjects) to 11.1 % (50 subjects), from 182.6 % (10 sub-
jects) to 67.3 % (50 subjects) and from 58.9 % (10 sub-
jects) to 32.5 % (50 subjects), respectively. Relative bias
for the R parameter estimate for these scenarios showed a
slight increase, from -6.9 % (10 subjects) to -8.5 % (50
subjects). The relative bias in the estimates of IIV in the
R parameter decreased from 43.5 % (10 subjects) to 32.4 %
(50 subjects) and the estimates of the residual error
remained approximately -20 % for all sample sizes.
The result from the slow distribution scenarios (13–24)
and the 1 sample per subject designs (scenarios 13–16)
showed an overall decrease in rRMSE for the parameter
estimates with increasing number of subjects. Relative bias
for the k and R parameter estimates on the other hand
increased following increased study population sizes. For
these scenarios (13–24), estimation of the rate parameter
k was possible in contrast to the fast distribution scenarios
(1–12), and included in the evaluation. rRMSE decreased
from 28 % (10 subjects) to 22 % (50 subjects), 21.8 % (10
subjects) to 14.5 % (50 subjects) and 69.6 % (10 subjects)
to 29.3 % (50 subjects) for estimates of k, R and the
residual error, respectively. Relative bias increased from
7.9 % (10 subjects) to 15.4 % (50 subjects) and -3.9 % (10
subjects) to -10.6 % (50 subjects) for estimates of k and R,
respectively. Relative bias in the residual error decreased
from -21.6 % (10 subjects) to -11 % (50 subjects). The
slow distribution rate scenarios (13–24) were also evalu-
ated using 2 samples per subject and varying the size of the
study population (scenarios 17–20). The rRMSE decreased
from 26 % (10 subjects) to 19.3 % (50 subjects), 17.3 %
(10 subjects) to 13.8 % (50 subjects) and 46.1 % (10
subjects) to 22.5 % (50 subjects) for estimates of k, R and
the residual error, respectively, and showing lower overall
Fig. 3 Relative root mean
square error (rRMSE) (left) and
relative bias (right) in the
estimate of the bronchoalveolar
lavage (BAL) fluid/plasma
concentration distribution ratio
(R) and the residual error for the
scenarios with fast distribution
and 1 sample per subject
(scenarios 1–4). The different
samples sizes are given in
different grey shades
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rRMSE values for the parameter estimates compared to the
1 sample per subject scenarios (13-16). Relative bias in the
k and R parameter estimates increased from 14.1 % (10
subjects) to 15.9 % (50 subjects) and -8.3 % (10 subjects)
to -10.6 (50 subjects). Relative bias for the residual error
decreased with increased sample size from -16 (10 sub-
jects) to -9.7 (50 subjects). The slow distribution with 2
samples per subjects was also evaluated with estimation of
IIV in R. The rRMSE for the parameter estimates of k, R,
IIV in R and the residual error decreased with increasing
sample size; 26.6 % (10 subjects) to 19.2 % (50 subjects);
22.4 % (10 subjects) to 18 % (50 subjects); 137.3 % (10
subjects) to 58.6 % (50 subjects) and 57.4 % (10 subjects)
to 28.5 % (50 subjects), respectively. The relative bias in
the k and R parameter estimates increased from 10.5 % (10
subjects) to 14.6 % (50 subjects) and -10.5 % (10 subjects)
to -15.9 % (50 subjects), respectively. Relative bias in the
IIV of R parameter estimates decreased with increased
number of subjects in the study population; 39.9% (10
subjects) to 24.5 % (50 subjects). A decrease in relative
bias was also observed in the residual error, -26.7 % (10
subjects) to -13 % (50 subjects).
Discussion
An optimized sampling design for BAL sampling have
been developed and evaluated for two different distribu-
tions scenarios, fast and slow, with respect to the impact of
different number of samples per subject and sample size.
Fig. 4 Relative root mean
square error (rRMSE) (left) and
relative bias (right) in the
estimate of the bronchoalveolar
lavage (BAL) fluid/plasma
concentration distribution ratio
(R) and the residual error for the
scenarios with fast distribution
and 2 sample per subject
(scenarios 5–8). The different
samples sizes are given in
different grey shades
Fig. 5 Relative root mean
square error (rRMSE) (left) and
relative bias (right) in the
estimate of the bronchoalveolar
lavage (BAL) fluid/plasma
concentration distribution ratio
(R), inter individual variability
in the R parameter (IIV R) and
the residual error for the
scenarios with fast distribution
and 2 sample per subject
(scenarios 9–12). The different
samples sizes are given in
different grey shades
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The sampling designs were investigated using a previously
published pharmacometric modeling approach for
describing pulmonary distribution [9]. The approach was
carried out using a model (Fig. 2) that included a previ-
ously published RIF plasma PK model [17] and a general
pulmonary distribution model (Eq. 3). Simulations with the
model using different distribution rate constants (Online
Resource 1) and distribution ratios (extents) (Online
Resource 2) showed that although the model represents a
simplistic approach to distribution characterization it is
very much capable of handling different distribution
properties such as different ELF and AC distribution rate
constants and or distribution ratios (extents). In this study a
general pulmonary distribution compartment (Eq. 3),
referred to as BAL fluid, was used to represent a hypo-
thetical scenario in which the distribution from plasma to
ELF or AC is either similar or a scenario in which only
ELF or AC is of interest. Evaluation of using joint or
separate ELF and AC distribution rate constants and dis-
tribution ratios (extents) should naturally be explored
during data analysis of observed clinical data.
The sampling design involves sampling at only 2 time
points, one early and one late and can be performed with
only 1 sample per subject in accordance with how most
BAL studies are performed. The sampling approach relies
on that the plasma concentration time profile of the studied
drug as well as that the LOQ for the drug concentration in
the BAL sample is known. In addition, a population
Fig. 6 Relative root mean
square error (rRMSE) (left) and
relative bias (right) in the
estimate of the distribution rate
constant for the transfer of drug
from the plasma to the
bronchoalveolar lavage (BAL)
fluid (k), the BAL fluid/plasma
concentration distribution ratio
(R) and the residual error for the
scenarios with slow distribution
and 1 sample per subject
(scenarios 13–16). The different
samples sizes are given in
different grey shades
Fig. 7 Relative root mean
square error (rRMSE) (left) and
relative bias (right) in the
estimate of the distribution rate
constant for the transfer of drug
from the plasma to the
bronchoalveolar lavage (BAL)
fluid (k), the BAL fluid/plasma
concentration distribution ratio
(R) and the residual error for the
scenarios with slow distribution
and 2 sample per subject
(scenarios 17–20). The different
samples sizes are given in
different grey shades
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pharmacokinetic model for plasma concentrations is nee-
ded. The time of sampling of the two samples is decided
based on usage of the drug specific plasma PK model and
needs to be exhibit correspondence in the early and the late
sample with regards to plasma concentration. The time of
the early sample should be as early as possible on the
ascending part of the concentration time profile, to maxi-
mize the chance of capturing fast distribution rates from
plasma to the pulmonary tract. However, one needs to
consider that a slow distribution might require taking the
first BAL sample at a later time point in order to reduce the
risk of pulmonary concentrations\LOQ. This leads to
that the late BAL sample will be taken earlier since it
should be taken at a time point where the plasma concen-
trations for the BAL samples are the same. Further if the
uncertainty in low concentrations is expected to be large it
is naturally advisable to move the sampling time point
further away from the LOQ. The late sample should be
taken on the descending part of the concentration time
profile at a time point where the plasma concentration is
similar to that of the sample from the ascending part. In
summary the decision of when to sample is carried in three
steps:
(1) A plasma concentration versus time profile is
simulated with the drug specific plasma PK model
(2) Pulmonary BAL concentrations is simulated using
the general pulmonary model [9] and an assumed
slow distribution rate (if the distribution is truly
perfusion limited i.e. fast, this assumption will not
impact the bias and precision in PK estimates as
shown in this work)
(3) One early and one late BAL sampling time points are
identified using the simulated plasma and BAL
concentrations versus time profiles and the BAL
LOQ. The two BAL sampling time points should be
taken when the plasma concentration is the same and
when the BAL samples are[BAL LOQ
As with all sampling designs, ensuring that concentra-
tions are above CLOQ at the time of sampling is important
when utilizing the suggested sampling design. Perhaps
even more so in this case as only two samples are taken for
the whole study population. As described in the methods
section, the early sample should be taken as early as pos-
sible, keeping in mind that the drug concentration still
needs to be CLOQ. For drugs with a perfusion rate limiting
distribution to the pulmonary tract, the raising part of the
profile of ELF or AC concentrations will follow the plasma
profile. For drugs with a permeability limited distribution
to the pulmonary tract characterized with a slow distribu-
tion rate, this will however naturally require a later early
sampling time to ensure pulmonary concentrations to
be CLOQ. In Online Resource 1, the ELF or AC profiles
for a pulmonary slow distribution with a k of 0.346 h is
shown. This is equivalent to slow distribution where the
distribution half-life is 2 h and steady-state in ELF would
be reached after 8–10 h. With such a slow distribution, the
maximal concentration in ELF is reached at approximately
8 h. Despite this slow distribution, the rate and extent of
distribution can be described given the proposed design.
Although less likely, in a scenario where the second sample
at approximately 13 h is higher than at the first sample, the
model approach [9] have no problems handling scenarios
where ELF or AC concentrations are higher at the late
sample time point compared to the early time point as the
plasma profile is known and linked to the general pul-
monary distribution model. The suggested sampling design
Fig. 8 Relative root mean
square error (rRMSE) (left) and
relative bias (right) in the
estimate of the distribution rate
constant for the transfer of drug
from the plasma to the
bronchoalveolar lavage (BAL)
fluid (k), the BAL fluid/plasma
concentration distribution ratio
(R), the inter individual
variability in the R parameter
(IIV R) and the residual error for
the scenarios with slow
distribution and 2 sample per
subject (scenarios 21–24). The
different samples sizes are given
in different grey shades
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together with the suggested modeling approach [9] is able
to describe pharmacokinetic data after different types of
administration and non-linear types of pulmonary distri-
bution, for example concentration dependent distribution.
In summary, the general pulmonary distribution model can
estimate the extent and rate of distribution given two
samples for any nonlinear pulmonary PK after any type of
route of administration given that there is a well charac-
terized plasma PK model for the route of administration.
The second sample can be taken even though maximum
pulmonary distribution has not yet occurred, as in the slow
distribution scenario in this work, since it is coupled to a
known plasma PK model. However, there are limitations
with using the pulmonary distribution model. Multiphasic
types of distribution can naturally not be described which
require a multi-compartmental type of description, which is
not supported by the approach or the sampling design.
However, multi-compartmental models are very unlikely to
be supported by the sparse data collected in BAL studies.
Further, it is not very likely to believe that peripheral
distribution within ELF or AC fluid to occur, which would
justify multiple-compartmental models.
The evaluation showed that regardless of distribution
rate the 2 samples per subject sampling design resulted in
lower rRMSE for all the parameter estimates compared to
the 1 sample per subject sampling design. Regardless of
number of samples per subject, an increase of the sample
size lead to a decrease in rRMSE in all parameter esti-
mates. For the slow distribution scenarios (13–24), an
increase in relative bias in the k and R parameter estimates
was observed when increasing the sample size. This
probably reflects a non-symmetric distribution of estimates
around the point estimate. To explore the impact of vari-
ability, in any of the distribution characterizing parameters
scenarios, on parameter precision scenarios including IIV
was included in the sampling design evaluation. In the
publication by Clewe et al [9], the data did not support any
variability in either R or k. In order to explore the impact of
variability in the extent of distribution (R) in this work, a
coefficient of variation (CV) of 30 % was assumed in R for
scenario (9–12, 21–24). The inclusion of IIV on R and not
k was purely hypothetical and this should naturally be
explored during data analysis of observed clinical data
obtained after a BAL study. Further the scenarios that
included estimation of IIV of the R parameter was only
conducted for the 2 samples per subject design due to that
at least 2 samples are needed to separate residual vari-
ability from IIV. As expected, the results from the evalu-
ation with inclusion of IIV, for both the fast and slow
distribution scenarios, showed similar trends with regards
to decreasing rRMSE for the parameter estimates with
increased sample size. For the slow distribution scenarios,
an increase in bias for the k and R parameter estimates
following increased sample size was observed. This
information alone implies that larger sample sizes generate
estimates further away from the true value. However, the
relative bias has to be considered together with the preci-
sion of the estimates (rRMSE) in order to make a fair
evaluation of the scenarios. In all scenarios where the
relative bias in parameter estimates increased the rRMSE
value decreased with increasing sample size.
The developed sampling design enables characterization
of the rate and extent of distribution from plasma to the
pulmonary tract making use of only one or two BAL samples
per subject. The approach is further applicable to situations
where little is known with regards to pulmonary distribution
properties and relies only pre-characterized plasma PK and
LOQ of the BAL technique. The approach was evaluated for
a general plasma to pulmonary distribution but is applicable
to distribution to either ELF, AC or both using adequate data,
a proper plasma PK model and in accordance with the data
analysis a proper set of pulmonary distribution models. The
evaluation of the sampling design revealed that two samples
per subject out-performs one sample per subject and that not
surprisingly, an increase in the sample size decreases the
relative RMSE in the parameter estimates. The results do
however suggest that the presented sampling design pro-
vides adequate precision in the parameter estimates using
only one sample per subject.
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